

12. Lee JM, Choi KH, Song YB, et al. Intravascular imaging-guided or angiography-guided complex PCI. *New England Journal of Medicine*. 2023 May 4;388(18):1668-79.
13. Sorajja P, Whisenant B, Hamid N, et al. Transcatheter repair for patients with tricuspid regurgitation. *New England Journal of Medicine*. 2023 May 18;388(20):1833-42.
14. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. *New England Journal of Medicine*. 2023 Nov 23;389(21):1949-60.
15. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. *New England Journal of Medicine*. 2020 Apr 9;382(15):1395-407.
16. Al-Lamee R, Thompson D, Dehbi HM, et al. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. *The Lancet*. 2018 Jan 6;391(10115):31-40.
17. Ajufo E, Nayak A, Mehra MR. Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions. *Basic to Translational Science*. 2023 Jun 1;8(6):720-7.
18. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 years after transcatheter aortic valve replacement in patients at low surgical risk. *Journal of the American College of Cardiology*. 2021 Mar 9;77(9):1149-61.
19. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. *Nature medicine*. 2022 Oct;28(10):2083-91.
20. Sattar N, Lee MM, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. *The Lancet Diabetes & endocrinology*. 2021 Oct 1;9(10):653-62.
21. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. *New England Journal of Medicine*. 2023 Dec 14;389(24):2221-32.
22. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. *New England Journal of Medicine*. 2022 Jul 21;387(3):205-16.
23. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *The Lancet*. 2023 Jun 26.
24. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. *JAMA*. 2024 Jan 2;331(1):38-48.
25. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *New England Journal of Medicine*. 2023 Apr 13;388(15):1353-64.
26. Bonaca MP, Hamburg NM, Creager MA. Contemporary medical management of peripheral artery disease. *Circulation research*. 2021 Jun 11;128(12):1868-84.
27. Farber A, Menard MT, Conte MS, et al. Surgery or endovascular therapy for chronic limb-threatening ischemia. *New England Journal of Medicine*. 2022 Dec 22;387(25):2305-16.
28. Cox Z, et al. DICTATE-AHF: Early Dapagliflozin Initiation in Acute Heart Failure. ESC Congress 2023, Amsterdam, European Society of Cardiology. <https://www.escardio.org/The-ESC/Press-Office/Press-releases/DICTATE-AHF-trial-fails-to-meet-primary-endpoint-with-dapagliflozin-in-acute-heart-failure>
29. Borlaug BA, Jensen MD, Kitzman DW, et al. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. *Cardiovascular Research*. 2022 Dec;118(18):3434-3450.
30. Kosiborod MN, Abildstrøm SZ, Borlaug BA, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. *New England Journal of Medicine*. 2023 Sep 21;389(12):1069-84.
31. Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. *New England Journal of Medicine*. 2023 Oct 12;389(15):1380-9.

CYKLUS SEMINÁŘŮ

31. interna informans

14. 5. Olomouc • 21. 5. Plzeň • 4. 6. Brno
11. 6. České Budějovice • 12. 6. Ústí nad Labem • 25. 6. Praha

Odborný garant



ČESKÁ
INTERNISTICKÁ
SPOLEČNOST

www.interna-informans.cz

Pořádá



NADAČNÍ
FOND
ČESKÉ
INTERNY